Back to results
US 10,646,599 B2Granted
Method for upregulating antigen expression
AssigneeNordic Nanovector Asa
InventorsRoy H. Larsen, Ada Repetto-Llamazares
Life of this patent
Estimating the term…
Abstract
The present invention relates to radioimmunoconjugates that are capable of upregulating expression of one or more antigens. The upregulated antigens can be the antigens that are targeted by the radioimmunoconjugates or different antigens expressed on the same cells. The present invention also relates to methods of treating cancer and diseases and disorders of the immune system by utilizing this enhanced expression of antigens.
Claims5
A method of sensitizing B-cell cancer cells in a person for an anti-CD20 drug comprising:
- administering to a person having B cell cancer cells, 177Lu-tetulomab (177Lu-HH1), and
- administering rituximab to said person 3-15 days after administration of the 177Lu-tetulomab (177Lu-HH1), wherein the 177Lu-tetulomab (177Lu-HH1) increases CD20 antigen expression in cancer cells.
Dependencies are inferred from the claim text.